Efficacy of angiotensin receptor neprilysin inhibitor in Asian patients with refractory hypertension
Abstract Sacubitril/valsartan, simultaneously inhibits neprilysin and angiotensin II receptor, showed an effect in reducing blood pressure (BP). The authors aimed to study whether it can be used as an antihypertensive agent in patients with refractory hypertension who have already been treated. A to...
| Hoofdauteurs: | , , , , , , , , , , |
|---|---|
| Formaat: | Artikel |
| Taal: | English |
| Gepubliceerd in: |
Wiley
2022-04-01
|
| Reeks: | The Journal of Clinical Hypertension |
| Onderwerpen: | |
| Online toegang: | https://doi.org/10.1111/jch.14454 |
| _version_ | 1827778918554271744 |
|---|---|
| author | Wanjing Li Minghui Gong Qin Yu Rihui Liu Kaiming Chen Wei Lv Fumei Yao Zhaolong Xu Yi Xu Wei Song Yinong Jiang |
| author_facet | Wanjing Li Minghui Gong Qin Yu Rihui Liu Kaiming Chen Wei Lv Fumei Yao Zhaolong Xu Yi Xu Wei Song Yinong Jiang |
| author_sort | Wanjing Li |
| collection | DOAJ |
| description | Abstract Sacubitril/valsartan, simultaneously inhibits neprilysin and angiotensin II receptor, showed an effect in reducing blood pressure (BP). The authors aimed to study whether it can be used as an antihypertensive agent in patients with refractory hypertension who have already been treated. A total of 66 Chinese patients with refractory hypertension were enrolled. Patients received sacubitril/valsartan 200 instead of angiotensin II receptor blocker or angiotensin converting enzyme inhibitor while other agents continued. If BP was uncontrolled after 4 weeks, sacubitril/valsartan was increased to 400 mg. The BP reduction was evaluated by office BP and ambulatory BP monitoring after 8‐week treatment. The baseline office BP and mean arterial pressure (MAP) were 150.0/95.0 mmHg and 113.3 mmHg. BP and MAP reduced to 130.6/83.2 mmHg and 99.0 mmHg at week 8. Office BP and MAP reductions were 19.4/11.8 mmHg and 14.3 mmHg at endpoint (all p < .001). The 24‐h, daytime and nighttime ambulatory BP were 146.2/89.1, 148.1/90.3, and 137.5/83.7 mmHg, respectively at baseline, and BP reduced to 129.6/79.8, 130.6/81.1, and 121.7/75.8 mmHg, respectively at week 8. The 24‐h, daytime and nighttime ambulatory BP reductions were 16.6/9.3, 17.5/9.2, and 15.8/7.9 mmHg, respectively at endpoint (all p < .001). Sacubitril/valsartan significantly reduced office and ambulatory BP in refractory hypertension patients. Our study provided new evidence for sacubitril/valsartan in refractory hypertension. |
| first_indexed | 2024-03-11T14:42:49Z |
| format | Article |
| id | doaj.art-e0f542cdc843488ba306c125aed68119 |
| institution | Directory Open Access Journal |
| issn | 1524-6175 1751-7176 |
| language | English |
| last_indexed | 2024-03-11T14:42:49Z |
| publishDate | 2022-04-01 |
| publisher | Wiley |
| record_format | Article |
| series | The Journal of Clinical Hypertension |
| spelling | doaj.art-e0f542cdc843488ba306c125aed681192023-10-30T13:26:43ZengWileyThe Journal of Clinical Hypertension1524-61751751-71762022-04-0124444945610.1111/jch.14454Efficacy of angiotensin receptor neprilysin inhibitor in Asian patients with refractory hypertensionWanjing Li0Minghui Gong1Qin Yu2Rihui Liu3Kaiming Chen4Wei Lv5Fumei Yao6Zhaolong Xu7Yi Xu8Wei Song9Yinong Jiang10Department of Cardiology The First Affiliated Hospital of Dalian Medical University Dalian Liaoning ChinaDepartment of Cardiology The First Affiliated Hospital of Dalian Medical University Dalian Liaoning ChinaDepartment of Cardiology The Affiliated Zhongshan Hospital of Dalian University Dalian Liaoning ChinaDepartment of Cardiology The Central Hospital of Liaoyang City Affiliated China Medical University Liaoyang Liaoning ChinaDepartment of Cardiology The Affiliated Central Hospital of Shenyang Medical College Shenyang Liaoning ChinaDepartment of Cardiology The Affiliated Shengjing Hospital of China Medical University Dalian Liaoning ChinaDepartment of Cardiology The Second People's Hospital of Dalian Dalian Liaoning ChinaDepartment of Cardiology The First Affiliated Hospital of Jinzhou Medical University Jinzhou Liaoning ChinaDepartment of Cardiology Dalian Locomotive Hospital Dalian Liaoning ChinaDepartment of Cardiology The First Affiliated Hospital of Dalian Medical University Dalian Liaoning ChinaDepartment of Cardiology The First Affiliated Hospital of Dalian Medical University Dalian Liaoning ChinaAbstract Sacubitril/valsartan, simultaneously inhibits neprilysin and angiotensin II receptor, showed an effect in reducing blood pressure (BP). The authors aimed to study whether it can be used as an antihypertensive agent in patients with refractory hypertension who have already been treated. A total of 66 Chinese patients with refractory hypertension were enrolled. Patients received sacubitril/valsartan 200 instead of angiotensin II receptor blocker or angiotensin converting enzyme inhibitor while other agents continued. If BP was uncontrolled after 4 weeks, sacubitril/valsartan was increased to 400 mg. The BP reduction was evaluated by office BP and ambulatory BP monitoring after 8‐week treatment. The baseline office BP and mean arterial pressure (MAP) were 150.0/95.0 mmHg and 113.3 mmHg. BP and MAP reduced to 130.6/83.2 mmHg and 99.0 mmHg at week 8. Office BP and MAP reductions were 19.4/11.8 mmHg and 14.3 mmHg at endpoint (all p < .001). The 24‐h, daytime and nighttime ambulatory BP were 146.2/89.1, 148.1/90.3, and 137.5/83.7 mmHg, respectively at baseline, and BP reduced to 129.6/79.8, 130.6/81.1, and 121.7/75.8 mmHg, respectively at week 8. The 24‐h, daytime and nighttime ambulatory BP reductions were 16.6/9.3, 17.5/9.2, and 15.8/7.9 mmHg, respectively at endpoint (all p < .001). Sacubitril/valsartan significantly reduced office and ambulatory BP in refractory hypertension patients. Our study provided new evidence for sacubitril/valsartan in refractory hypertension.https://doi.org/10.1111/jch.14454ambulatory blood pressure monitoringangiotensin receptor neprilysin inhibitorAsiarefractory hypertensionsacubitril/valsartan |
| spellingShingle | Wanjing Li Minghui Gong Qin Yu Rihui Liu Kaiming Chen Wei Lv Fumei Yao Zhaolong Xu Yi Xu Wei Song Yinong Jiang Efficacy of angiotensin receptor neprilysin inhibitor in Asian patients with refractory hypertension The Journal of Clinical Hypertension ambulatory blood pressure monitoring angiotensin receptor neprilysin inhibitor Asia refractory hypertension sacubitril/valsartan |
| title | Efficacy of angiotensin receptor neprilysin inhibitor in Asian patients with refractory hypertension |
| title_full | Efficacy of angiotensin receptor neprilysin inhibitor in Asian patients with refractory hypertension |
| title_fullStr | Efficacy of angiotensin receptor neprilysin inhibitor in Asian patients with refractory hypertension |
| title_full_unstemmed | Efficacy of angiotensin receptor neprilysin inhibitor in Asian patients with refractory hypertension |
| title_short | Efficacy of angiotensin receptor neprilysin inhibitor in Asian patients with refractory hypertension |
| title_sort | efficacy of angiotensin receptor neprilysin inhibitor in asian patients with refractory hypertension |
| topic | ambulatory blood pressure monitoring angiotensin receptor neprilysin inhibitor Asia refractory hypertension sacubitril/valsartan |
| url | https://doi.org/10.1111/jch.14454 |
| work_keys_str_mv | AT wanjingli efficacyofangiotensinreceptorneprilysininhibitorinasianpatientswithrefractoryhypertension AT minghuigong efficacyofangiotensinreceptorneprilysininhibitorinasianpatientswithrefractoryhypertension AT qinyu efficacyofangiotensinreceptorneprilysininhibitorinasianpatientswithrefractoryhypertension AT rihuiliu efficacyofangiotensinreceptorneprilysininhibitorinasianpatientswithrefractoryhypertension AT kaimingchen efficacyofangiotensinreceptorneprilysininhibitorinasianpatientswithrefractoryhypertension AT weilv efficacyofangiotensinreceptorneprilysininhibitorinasianpatientswithrefractoryhypertension AT fumeiyao efficacyofangiotensinreceptorneprilysininhibitorinasianpatientswithrefractoryhypertension AT zhaolongxu efficacyofangiotensinreceptorneprilysininhibitorinasianpatientswithrefractoryhypertension AT yixu efficacyofangiotensinreceptorneprilysininhibitorinasianpatientswithrefractoryhypertension AT weisong efficacyofangiotensinreceptorneprilysininhibitorinasianpatientswithrefractoryhypertension AT yinongjiang efficacyofangiotensinreceptorneprilysininhibitorinasianpatientswithrefractoryhypertension |